<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240629062277N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-07-13</date_registration>
      <primary_sponsor>Zabol University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effectiveness of aromatherapy with orange and geranium essential oil on sleep quality and anxiety in Thalassemia</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of aromatherapy with orange and geranium essential oil on sleep quality and anxiety in patients with major thalassemia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/77769</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Simple randomization (toss a coin)
In this way, first a list of patients who meet the research inclusion criteria will be prepared, in this study 3 groups numbers 1 and 2 for the first group of orange essential oil, numbers 3 and 4 for the second group of geranium essential oil and numbers 5 and 6 for the third group (control) will be considered. is taken and this work will continue until all research samples are placed in one of the intervention and control groups, Blinding description: This study will be conducted in the form of a blind controlled clinical trial (this means that the subjects do not know which groups they are in).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Thalassemia major.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: For the purpose of aromatherapy, the first group is exposed to orange extract produced by Barij Essan Company of Kashan, which is prepared from orange peel and contains limonene, flandrene, citral (based on the presence of at least 18 mg of limonene per milliliter of the product).The intervention will be that 3 drops of essential oil will be poured on a sterile gauze, then the patient will be asked to smell the pad for one minute. After that, the gauze is fastened with a pin on a pillow or clothes at a distance of 20-25 cm from the patient's head; to smell it during three shifts and also during sleep.Aromatherapy sessions in the intervention groups are conducted three days a week (Saturday, Monday and Wednesday) and three times a day (10 am, 4 pm and at night before bedtime) for 4 weeks. Intervention 2: Intervention group2: Intervention group: The second group will be exposed to geranium extract produced by Tabib Daru Company. Geranium essential oil contains alphapinene (1.35%), citronellol (37.53%), geraniol (7.2%) and citronol formate (10.03%). The intervention will be that 3 drops of essential oil will be poured on a sterile gauze, then the patient will be asked to smell the pad for one minute. After that, the gauze is fastened with a pin on a pillow or clothes at a distance of 20-25 cm from the patient's head; to smell it during three shifts and also during sleep. Aromatherapy sessions in the intervention groups are conducted three days a week (Saturday, Monday and Wednesday) and three times a day (10 am, 4 pm and at night before bedtime) for 4 weeks. Intervention 3: Control group: In the control group, sweet almond oil will be used. This oil is obtained from a pharmacy and is completely odorless. In similar studies, this substance has been used for the control group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hajare Rigi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and midwifery school, next to Civil Registry Office, No.11 Ferdowsi St,</address>
        <city>Zabol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>98616615881</zip>
        <telephone>+98 54 3222 3948</telephone>
        <email>ha_rigi@zbmu.ac.ir</email>
        <affiliation>Zabol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdieh poodineh Moghadam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and midwifery school, next to Civil Registry Office, No.11 Ferdowsi St,</address>
        <city>Zabol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9861734184</zip>
        <telephone>+98 54 3222 3947</telephone>
        <email>moghadam07@yahoo.com</email>
        <affiliation>Zabol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Definitive diagnosis of major Thalassemia 
Having minimum reading and writing literacy
Absence of events and sudden stressful life conditions during the past 6 months
Not having known breathing problems such as asthma, not having an olfactory disorder
Not suffering from mental illnesses
Not addicted to drugs, alcohol and cigarettes
Not using sedatives
No history of eczema and allergy to plants
Satisfaction with participating in the study
Not using other aroma therapy methods during the study period
Patients who have sleep disorders and anxiety according to the questionnaires</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: For the purpose of aromatherapy, the first group is exposed to orange extract produced by Barij Essan Company of Kashan, which is prepared from orange peel and contains limonene, flandrene, citral (based on the presence of at least 18 mg of limonene per milliliter of the product).The intervention will be that 3 drops of essential oil will be poured on a sterile gauze, then the patient will be asked to smell the pad for one minute. After that, the gauze is fastened with a pin on a pillow or clothes at a distance of 20-25 cm from the patient's head; to smell it during three shifts and also during sleep.Aromatherapy sessions in the intervention groups are conducted three days a week (Saturday, Monday and Wednesday) and three times a day (10 am, 4 pm and at night before bedtime) for 4 weeks.</i_keyword>
      <i_keyword>Intervention group2: Intervention group: The second group will be exposed to geranium extract produced by Tabib Daru Company. Geranium essential oil contains alphapinene (1.35%), citronellol (37.53%), geraniol (7.2%) and citronol formate (10.03%). The intervention will be that 3 drops of essential oil will be poured on a sterile gauze, then the patient will be asked to smell the pad for one minute. After that, the gauze is fastened with a pin on a pillow or clothes at a distance of 20-25 cm from the patient's head; to smell it during three shifts and also during sleep. Aromatherapy sessions in the intervention groups are conducted three days a week (Saturday, Monday and Wednesday) and three times a day (10 am, 4 pm and at night before bedtime) for 4 weeks.</i_keyword>
      <i_keyword>Control group: In the control group, sweet almond oil will be used. This oil is obtained from a pharmacy and is completely odorless. In similar studies, this substance has been used for the control group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety score. Timepoint: Before the intervention and every week until the end of the fourth week. Method of measurement: state-trait anxiety inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sleep quality score. Timepoint: Before the intervention and one week after the intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zabol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-06</approval_date>
        <contact_name>Ethics committee of Zabol University of Medical Sciences</contact_name>
        <contact_address>Research Vice-Chancellor of the University, Shahid Rajaei St. Zabol Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
